Surgery Partners, Inc.

Fundamentals4.0
Price Action7.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Interest Coverage
  • Margin Pressure
  • Debt Burden

AI
AI Summary

5.0

SGRY should be viewed less as a cheap healthcare stock and more as a leveraged outpatient surgery platform whose rerating hinges on converting resilient same-facility growth into sustained free cash flow and materially better interest coverage, because the current valuation only works if margins stabilize before heavy debt and cost pressure erode earnings quality.

Turnaround
Leverage
Healthcare‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • Interest Coverage
  • Margin Pressure
  • Debt Burden

SGRY generated solid annual cash flow but weakening quarterly margins, persistent losses, and heavy debt/interest burden leave its earnings and balance sheet outlook fragile.

LeverageRisk
CashFlow

Price Behavior

7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Breakout trend
  • Overextended run
  • Nearby support

SGRY has broken out into a strong last month uptrend, but after a ~28% run it looks stretched and may pause or consolidate near $16.56-$16.80.

bullish
watchlist
Support Level: $16.56-$16.80
Resistance Level: $17.23

Rapid ~28% rise from $13.51 to $17.23 over last month suggests short-term volatility risk

Sentiment & News

6.0

Key News Insights:

  • Analyst Upside
  • Improving Estimates
  • Scale Advantage

Surgery Partners is attracting constructive attention as a reasonably priced momentum stock, backed by analyst upside, improving estimates, and its large outpatient care network.

SGRY
Bullish

The latest headlines likely reinforce investor confidence in SGRY by highlighting both valuation appeal and operational scale